Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Subcutaneous medication of tarlatamab was good tolerated and demonstrated preliminary antitumor enactment successful patients with antecedently treated extensive-stage tiny compartment lung crab (ES-SCLC), according to findings from the signifier 1b DeLLphi-308 survey presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).